{"id":"https://openalex.org/W2282926083","doi":null,"title":"Utvikling av en analysemetode for vinkristin i plasma","display_name":"Utvikling av en analysemetode for vinkristin i plasma","publication_year":2007,"publication_date":"2007-01-01","ids":{"openalex":"https://openalex.org/W2282926083","mag":"2282926083"},"language":"no","primary_location":{"id":"pmh:oai:www.duo.uio.no:10852/12191","doi":null,"is_oa":true,"landing_page_url":"http://hdl.handle.net/10852/12191","pdf_url":"http://hdl.handle.net/10852/12191","source":{"id":"https://openalex.org/S7407064446","display_name":"NORA - Norwegian Open Research Archives","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"info:eu-repo/semantics/masterThesis"},"volume":null,"type":"dissertation","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"http://hdl.handle.net/10852/12191","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5037674011","display_name":"Stine Hiller Eidnes","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Stine Hiller Eidnes","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5037674011"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.4771000146865845,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.4771000146865845,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11460","display_name":"Analytical Methods in Pharmaceuticals","score":0.40939998626708984,"subfield":{"id":"https://openalex.org/subfields/1602","display_name":"Analytical Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.012600000016391277,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/vincristine","display_name":"vincristine","score":0.9520000219345093},{"id":"https://openalex.org/keywords/m1-metabolite","display_name":"M1 metabolite","score":0.734000027179718},{"id":"https://openalex.org/keywords/plasma-drug-concentration","display_name":"plasma drug concentration","score":0.6800000071525574},{"id":"https://openalex.org/keywords/peripheral-neuropathy","display_name":"peripheral neuropathy","score":0.9190000295639038},{"id":"https://openalex.org/keywords/cyp3a5","display_name":"CYP3A5","score":0.8299999833106995},{"id":"https://openalex.org/keywords/p-glycoprotein","display_name":"P-glycoprotein","score":0.953000009059906},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7239999771118164},{"id":"https://openalex.org/keywords/lc-ms-method-development","display_name":"LC-MS method development","score":0.7490000128746033},{"id":"https://openalex.org/keywords/cyp3a5-polymorphism","display_name":"CYP3A5 polymorphism","score":0.5070000290870667},{"id":"https://openalex.org/keywords/hodgkin-lymphoma","display_name":"Hodgkin's disease","score":0.9430000185966492},{"id":"https://openalex.org/keywords/non-hodgkin-lymphoma","display_name":"non-Hodgkin lymphoma","score":1.0}],"concepts":[{"id":"https://openalex.org/C178550888","wikidata":"https://www.wikidata.org/wiki/Q2043282","display_name":"Business administration","level":1,"score":0.3680986166000366},{"id":"https://openalex.org/C17744445","wikidata":"https://www.wikidata.org/wiki/Q36442","display_name":"Political science","level":0,"score":0.3245566487312317},{"id":"https://openalex.org/C144133560","wikidata":"https://www.wikidata.org/wiki/Q4830453","display_name":"Business","level":0,"score":0.2928217649459839}],"mesh":[],"locations_count":2,"locations":[{"id":"pmh:oai:www.duo.uio.no:10852/12191","doi":null,"is_oa":true,"landing_page_url":"http://hdl.handle.net/10852/12191","pdf_url":"http://hdl.handle.net/10852/12191","source":{"id":"https://openalex.org/S7407064446","display_name":"NORA - Norwegian Open Research Archives","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"info:eu-repo/semantics/masterThesis"},{"id":"mag:2282926083","doi":null,"is_oa":false,"landing_page_url":"https://www.duo.uio.no/handle/10852/12191","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":{"id":"pmh:oai:www.duo.uio.no:10852/12191","doi":null,"is_oa":true,"landing_page_url":"http://hdl.handle.net/10852/12191","pdf_url":"http://hdl.handle.net/10852/12191","source":{"id":"https://openalex.org/S7407064446","display_name":"NORA - Norwegian Open Research Archives","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"info:eu-repo/semantics/masterThesis"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9476000070571899,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2282926083.pdf","grobid_xml":"https://content.openalex.org/works/W2282926083.grobid-xml"},"referenced_works_count":46,"referenced_works":["https://openalex.org/W101728102","https://openalex.org/W119374870","https://openalex.org/W1517459426","https://openalex.org/W1645667097","https://openalex.org/W1754065147","https://openalex.org/W1795306802","https://openalex.org/W1988945250","https://openalex.org/W1989899433","https://openalex.org/W1993599833","https://openalex.org/W1994226708","https://openalex.org/W2006376126","https://openalex.org/W2007615684","https://openalex.org/W2010442385","https://openalex.org/W2011720547","https://openalex.org/W2016347738","https://openalex.org/W2021775978","https://openalex.org/W2027549508","https://openalex.org/W2031918167","https://openalex.org/W2033117707","https://openalex.org/W2036228589","https://openalex.org/W2046937425","https://openalex.org/W2052862609","https://openalex.org/W2065094929","https://openalex.org/W2076844582","https://openalex.org/W2080493963","https://openalex.org/W2085646040","https://openalex.org/W2091870271","https://openalex.org/W2109257139","https://openalex.org/W2113331331","https://openalex.org/W2118431766","https://openalex.org/W2122630078","https://openalex.org/W2126772533","https://openalex.org/W2127469009","https://openalex.org/W2127933783","https://openalex.org/W2133390829","https://openalex.org/W2137745279","https://openalex.org/W2138603774","https://openalex.org/W2140695271","https://openalex.org/W2144843163","https://openalex.org/W2157184495","https://openalex.org/W2163636362","https://openalex.org/W2164539379","https://openalex.org/W2293082234","https://openalex.org/W2323071534","https://openalex.org/W2327762756","https://openalex.org/W3003085797"],"related_works":["https://openalex.org/W2094253816","https://openalex.org/W3165277870","https://openalex.org/W4384007145","https://openalex.org/W2066085688","https://openalex.org/W4309175904","https://openalex.org/W3082987945","https://openalex.org/W2147297640","https://openalex.org/W2164488758","https://openalex.org/W1608524646","https://openalex.org/W4362543464"],"abstract_inverted_index":{"Sammendrag\\nBakgrunn:":[0],"Vinkristin":[1],"(VCR)":[2],"er":[3,22,62,69,84,94,128,355,531],"et":[4,462],"kjemoterapeutikum":[5],"som":[6,59,93,144,158,186,354,431,446,479],"benyttes":[7,146],"i":[8,64,96,142,150,215,226,238,348,350,436,448,468,503],"behandling":[9],"av":[10,50,76,80,98,112,138,194,199,209,213,256,280,297,305,368,373,398,415,470,484,499,516],"blant":[11,60],"annet":[12,61],"Hodgkin":[13],"lymfom":[14,18],"(HL)":[15],"og":[16,26,47,67,82,114,122,133,140,160,173,196,273,275,308,332,342,391,501,540],"non-Hodgkin":[17],"(NHL).":[19],"Perifer":[20],"nevropati":[21,116],"dosebegrensende":[23],"for":[24,105,136,176,192,206,254,337,356,358,371,450,464,496,509],"VCR-terapi,":[25],"\u00e5rsak":[27],"til":[28,37,74,88,147,284,457,482],"at":[29],"flere":[30],"pasienter":[31,118],"m\u00e5":[32],"seponere":[33],"behandling.":[34],"VCR":[35,113,139,214,346,399,471,500],"metaboliseres":[36],"den":[38,89,361,522],"antatte":[39],"hovedmetabolitten":[40],"M1":[41,141,153,179,281,309,485,502],"via":[42],"cytokrom":[43,174],"P450":[44],"3A":[45],"(CYP3A),":[46],"da":[48],"spesielt":[49],"det":[51,250,313,403,426,530],"genetisk":[52],"polymorfe":[53],"enzymet":[54],"CYP3A5.":[55],"Transportproteinet":[56],"P-glykoprotein":[57],"(P-gp),":[58],"uttrykt":[63],"blod-hjernebarrieren,":[65],"galle":[66],"lever,":[68],"ogs\u00e5":[70,460],"observert":[71,95],"\u00e5":[72,86,106,129,177,242,285,292,338,420,451,465,510],"bidra":[73,87],"eliminasjon":[75,97],"VCR.":[77,99,181],"Varierende":[78],"utrykk":[79],"CYP3A5":[81,172],"P-gp":[83],"mistenkt":[85],"store":[90],"intraindividuelle":[91],"variasjonen":[92],"Rikshospitalet-Radiumhospitalet":[100],"HF":[101],"har":[102],"initiert":[103],"VINCA-studien":[104],"se":[107],"p\u00e5":[108,231,247,320,360,389,472,542],"sammenhengen":[109],"mellom":[110],"plasmakonsentrasjon":[111],"perifer":[115],"hos":[117],"diagnostisert":[119],"med":[120,125,171,184,224,236,317,382,386,423,488,518,533],"HL":[121],"NHL.":[123],"Hensikten":[124],"denne":[126,262],"oppgaven":[127],"utvikle":[130],"en":[131,222,315,383,428,477],"sensitiv":[132,204,494],"robust":[134],"metode":[135],"deteksjon":[137,359,469],"plasma,":[143],"skal":[145],"farmakokinetiske":[148],"m\u00e5linger":[149],"VINCA-studien.\\n":[151],"\\nMetodeutvikling:":[152],"finnes":[154],"ikke":[155,203,493],"kommersielt":[156],"tilgjengelig":[157],"renstoff,":[159],"m\u00e5tte":[161],"produseres":[162],"preparativt.":[163],"Det":[164,218,474],"ble":[165,190,219,234,249,264,282,299,312,326,380,406,475,480,507],"benyttet":[166,481],"mikrosomer":[167],"fra":[168,180,455,486,544],"insektceller":[169],"ko-transfektert":[170],"b5":[175],"produsere":[178],"En":[182,505],"LC-UV-metode":[183,478],"vinblastin":[185],"intern":[187],"standard":[188],"(IS)":[189],"utviklet":[191,221,230,314,476],"analyse":[193,341],"metabolismefors\u00f8kene":[195],"preparativ":[197],"isolering":[198,483],"M1.":[200],"LC-UV-metoden":[201],"var":[202,393,492],"nok":[205,495,527],"kvantitative":[207,497],"analyser":[208,498],"pasientpr\u00f8ver":[210],"etter":[211],"administrasjon":[212],"terapeutiske":[216],"doser.":[217],"derfor":[220],"LC-MS-metode":[223,506],"utgangspunkt":[225],"de":[227],"kromatografiske":[228],"betingelsene":[229],"LC-UV.":[232],"MS-deteksjonen":[233],"foretatt":[235],"elektrospray-ionisasjon":[237,456],"positiv":[239],"mode.":[240],"For":[241,303,419],"oppn\u00e5":[243,339,511],"tilstrekkelig":[244],"lav":[245],"deteksjonsgrense":[246],"LC-MS-analyse":[248],"testet":[251],"ut":[252],"prosedyrer":[253],"oppkonsentrering":[255,372,515],"plasmapr\u00f8ver":[257,374],"ved":[258,310,395,417],"fast":[259,266,369,387,437,519],"fase-ekstraksjon.":[260],"I":[261,324,366,402,439],"uttestingen":[263,367],"ulike":[265],"fase-kolonner":[267],"evaluert":[268],"(C2,":[269],"C18,":[270],"Oasis":[271],"HLB":[272],"Strata-X).\\n\\nResultat":[274],"diskusjon:":[276],"Den":[277],"isolerte":[278],"mengden":[279],"kvantifisert":[283],"v\u00e6re":[286,293,461],"1,05":[287],"\uf06dg/ml.":[288],"Produktet":[289],"viste":[290,375],"seg":[291],"rent,":[294],"men":[295,490,529],"utbyttet":[296],"metabolitten":[298],"lavere":[300,404],"enn":[301],"forventet.":[302],"grunnlinjeseparasjon":[304],"VCR,":[306,489],"IS":[307],"LC-UV-analyser":[311],"mobilfasegradient":[316],"maksimal":[318],"stigning":[319],"0,77":[321],"%":[322,330],"MeOH/min.":[323],"LC-MS-metoden":[325,363,524],"mobilfasegradienten":[327],"(maksimalt":[328],"10":[329],"MeOH/min)":[331],"mobilfasehastigheten":[333],"(0,15":[334],"ml/min)":[335],"optimalisert":[336],"rask":[340],"lavest":[343],"mulig":[344,434],"deteksjonsgrense.":[345],"forekommer":[347],"plasmakonsentrasjoner":[349],"omr\u00e5det":[351],"0,1-2,5":[352],"ng/ml,":[353],"lave":[357],"utviklede":[362,523],"uten":[364],"oppkonsentrering.":[365],"fase-prosedyre":[370],"C18-kolonner":[376,390],"best":[377],"resultat.":[378],"Plasma":[379],"oppkonsentrert":[381],"faktor":[384],"6-7":[385],"fase-ekstraksjoner":[388],"gjenfinningen":[392,408],"god":[394,526],"h\u00f8y":[396],"konsentrasjon":[397],"(80":[400],"%).":[401],"konsentrasjonsomr\u00e5det":[405],"imidlertid":[407],"sv\u00e6rt":[409],"d\u00e5rlig.":[410],"Dette":[411],"kan":[412,425,441,459,538],"skyldes":[413],"signalsuppresjon":[414,424],"plasmakomponenter":[416,435],"MS-deteksjon.":[418],"unng\u00e5":[421],"problemer":[422],"fors\u00f8kes":[427],"grundigere":[429],"vaskeprosess":[430],"fjerner":[432],"flest":[433],"fase-opparbeidelsen.":[438],"tillegg":[440],"kjemisk":[442],"ionisasjon":[443],"(AP-CI)":[444],"testes":[445],"deteksjonsprisnipp":[447],"MS-analysen":[449],"begrense":[452],"signalsuppresjon.":[453],"Endring":[454],"AP-CI":[458],"tiltak":[463],"forbedre":[466],"sensitiviteten":[467],"LC-MS.\\n\\nKonklusjon:":[473],"metabolismefors\u00f8k":[487],"metoden":[491],"plasmapr\u00f8ver.":[504],"videreutviklet":[508],"bedre":[512],"sensitivitet.":[513],"Med":[514],"plasmapr\u00f8vene":[517],"fase-ekstraksjon":[520],"b\u00f8r":[521],"gi":[525],"deteksjon,":[528],"n\u00f8dvendig":[532],"ytterligere":[534],"uttesting":[535],"f\u00f8r":[536],"analysemetoden":[537],"valideres":[539],"anvendes":[541],"pr\u00f8vene":[543],"VINCA-studien.":[545]},"counts_by_year":[],"updated_date":"2026-09-03T10:48:47.769340","created_date":"2016-06-24T00:00:00"}